EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Mirikizumab is Equally Effective in Ustekinumab-Exposed and Ustekinumab-Naïve Patients with UC: A Multicentre Real-World Cohort

Mohmmed Tauseef Sharip, Dharmaraj Durai, Eva Vayreda, Nurulamin M Noor, Anushka Herath, Achini Withanachchi, Robin Dart, Sreedhar Subramanian, Miles Parkes, Mark A Samaan, Tim Raine, Peter M Irving

Crohn's & Colitis 360 · 2026-06-19

DOI: 10.1093/crocol/otag065 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Mirikizumab, a selective IL-23p19 monoclonal antibody, has demonstrated efficacy in moderate-to-severe ulcerative colitis (UC) although real-world data are limited. In addition, registrational trials excluded patients previously treated with ustekinumab, which targets the IL-12/23 p40 subunit. We aimed to evaluate the real-world effectiveness and safety of mirikizumab in a multicentre UK cohort of patients with UC, including those with prior ustekinumab exposure. Methods A retrospective observational study was conducted across three tertiary UK centres. Adults with confirmed UC who received mirikizumab and had ≥12 weeks of follow-up were included. Data on demographics, disease activity (SCCAI, UCEIS), biomarkers (CRP, faecal calprotectin), and treatment persistence were analysed at 3 and 6 months. Outcomes were compared between ustekinumab-exposed and -naïve patients. Results Among 100 patients (36 ustekinumab-exposed), treatment persistence at 3 months was 72% with no significant difference between groups. SCCAI scores decreased from 5.8 to 3.3 at 3 months (p < 0.00001), and faecal calprotectin decreased from 1094 µg/g to 586 µg/g (p = 0.006). UCEIS scores (n = 36) improved significantly post-induction (mean 4.4 to 2.7, p < 0.000001). Multivariable logistic regression did not reveal any factors associated with treatment persistence, including prior ustekinumab exposure. Adverse events were infrequent and mild. Conclusion Mirikizumab is effective and well tolerated in a real-world UC population, including patients with prior ustekinumab exposure. These findings support the use of IL-23p19 inhibition regardless of previous IL-12/23 blockade.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →